Datapoint: Sarclisa to Compete with Darzalex in Multiple Myeloma

The FDA last week approved Sanofi’s Sarclisa (in tandem with Amgen’s Kyprolis and dexamethasone) for the treatment of relapsed or refractory multiple myeloma in patients who have had at least one prior treatment. This will put Sarclisa in direct competition with Johnson & Johnson’s Darzalex, which scored the same indication in August 2020. For the treatment of multiple myeloma, Darzalex currently holds preferred formulary placement for 7% of covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 4/5/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 11

Datapoint: Sentara to Open Community Care Centers, Launch New Model

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today